Results 111 to 120 of about 734,599 (256)

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink   +6 more
wiley   +1 more source

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

open access: yesCommunications Medicine
Background We developed the FORCETM platform to overcome limitations of oligonucleotide delivery to muscle and enable their applicability to neuromuscular disorders.
Timothy Weeden   +30 more
doaj   +1 more source

Screening polyoxometalates as aquaporin inhibitors for cancer therapeutics [PDF]

open access: yes, 2019
Aquaporins (AQPs) are transmembrane protein channels that facilitate the diffusion of water and glycerol across cell membranes, crucial for water and energy homeostasis.
Aureliano, M.   +4 more
core  

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

open access: yesMolecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi   +3 more
wiley   +1 more source

Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution

open access: yesNature Communications
Blood brain barrier-crossing molecules targeting transferrin receptor (TfR) and CD98 heavy chain (CD98hc) are widely reported to promote enhanced brain delivery of therapeutics.
Nathalie Khoury   +33 more
doaj   +1 more source

At the edge of individual cognitive-behavioural policies: how to walk the public health path to effectively improve population health?

open access: yesSalud Pública de México, 2013
Most countries worldwide have recognised the significance of contextual social determinants of health (SDH) on population health. This essay challenges current public health views focused on individual risk-factors and motivates an  evidenceinformed ...
Baltica Cabieses
doaj   +1 more source

Pediatric Obesity: Influence on Drug Dosing and Therapeutics [PDF]

open access: yes, 2018
Obesity is an ongoing global health concern and has only recently been recognized as a chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US children and adolescents.
Ameer, Barbara, PharmD, MBA, BCPS, FCP   +1 more
core   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

open access: yes, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John   +4 more
core  

Home - About - Disclaimer - Privacy